166 related articles for article (PubMed ID: 8162617)
1. In vitro purging of clonogenic leukaemic cells from human bone marrow by interferon-gamma-activated monocytes.
van de Loosdrecht AA; Ossenkoppele GJ; Beelen RH; Broekhoven MG; Schweitzer KM; Langenhuijsen MM
Cancer Immunol Immunother; 1994 May; 38(5):346-52. PubMed ID: 8162617
[TBL] [Abstract][Full Text] [Related]
2. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
[TBL] [Abstract][Full Text] [Related]
3. Effective purging of bone marrow by a combination of immunorosette depletion and complement lysis.
Slaper-Cortenbach IC; Admiraal LG; van Leeuwen EF; Kerr JM; von dem Borne AE; Tetteroo PA
Exp Hematol; 1990 Jan; 18(1):49-54. PubMed ID: 2298269
[TBL] [Abstract][Full Text] [Related]
4. Specific binding of anti-N-acetyllactosamine monoclonal antibody 1B2 to acute myeloid leukaemia cells.
Campos L; Portoukalian J; Bonnier S; Shi ZH; Calmard-Oriol P; Treille D; Guyotat D
Eur J Cancer; 1992; 28(1):37-41. PubMed ID: 1567687
[TBL] [Abstract][Full Text] [Related]
5. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Margolin KA; Wright C; Forman SJ
Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
[TBL] [Abstract][Full Text] [Related]
6. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells.
Roy DC; Griffin JD; Belvin M; Blättler WA; Lambert JM; Ritz J
Blood; 1991 Jun; 77(11):2404-12. PubMed ID: 2039821
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative activity of quercetin on normal bone marrow and leukaemic progenitors.
Larocca LM; Teofili L; Leone G; Sica S; Pierelli L; Menichella G; Scambia G; Benedetti Panici P; Ricci R; Piantelli M
Br J Haematol; 1991 Dec; 79(4):562-6. PubMed ID: 1772777
[TBL] [Abstract][Full Text] [Related]
8. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro.
van den Brink MR; Voogt PJ; Marijt WA; van Luxemburg-Heys SA; van Rood JJ; Brand A
Blood; 1989 Jul; 74(1):354-60. PubMed ID: 2787676
[TBL] [Abstract][Full Text] [Related]
10. Potential of phenylalanine methylester as a bone marrow purging agent.
Rosenfeld CS
Blood; 1992 Nov; 80(9):2401-5. PubMed ID: 1384802
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors.
Cazzola M; Bergamaschi G; Dezza L; D'Uva R; Ponchio L; Rosti V; Ascari E
Cancer Res; 1991 Jan; 51(2):536-41. PubMed ID: 1985771
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of colony-forming unit assays for engraftment and leukemia-free survival after transplantation of chemopurged syngeneic bone marrow in rats.
Wiley JM; Yeager AM
Exp Hematol; 1991 Mar; 19(3):179-84. PubMed ID: 1704843
[TBL] [Abstract][Full Text] [Related]
13. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
Wisniewski D; Strife A; Atzpodien J; Clarkson BD
Cancer Res; 1987 Sep; 47(18):4788-94. PubMed ID: 3040231
[TBL] [Abstract][Full Text] [Related]
14. Effect of mast cell growth factor (c-kit ligand) on clonogenic leukemic precursor cells.
Goselink HM; Williams DE; Fibbe WE; Wessels HW; Beverstock GC; Willemze R; Falkenburg JH
Blood; 1992 Aug; 80(3):750-7. PubMed ID: 1638026
[TBL] [Abstract][Full Text] [Related]
15. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
[TBL] [Abstract][Full Text] [Related]
16. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
Miller JS; Verfaillie C; McGlave P
Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
[TBL] [Abstract][Full Text] [Related]
17. Maturation-dependent susceptibility to monocyte-mediated cytotoxicity in acute myeloid leukemia.
van de Loosdrecht AA; Ossenkoppele GJ; Beelen RH; Broekhoven MG; van Hooff MH; Dräger AM; Huijgens PC; Langenhuijsen MM
Leukemia; 1994 Aug; 8(8):1392-400. PubMed ID: 8057679
[TBL] [Abstract][Full Text] [Related]
18. Clonogenic hemopoietic precursors in bone marrow transplantation.
Messner HA; Curtis JE; Minden MD; Tritchler D; Lockwood G; Takahashi T; Lepine J; Jamal N; Tweeddale M; Wandl U
Blood; 1987 Nov; 70(5):1425-32. PubMed ID: 3311204
[TBL] [Abstract][Full Text] [Related]
19. Elimination of clonogenic tumor cells from HL-60, Daudi, and U-937 cell lines by laser photoradiation therapy: implications for autologous bone marrow purging.
Gulliya KS; Pervaiz S
Blood; 1989 Mar; 73(4):1059-65. PubMed ID: 2920207
[TBL] [Abstract][Full Text] [Related]
20. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
